UBS Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

UBS Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-100,000	Closed	-$2.51M	–	11436
2022 Q3	$2.51M	Buy	+100,000	New	+$2.77M	﹤0.01%	2959

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's RETA Position: Q3 2023 in Review

UBS Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 39,027 shares — an estimated $3.98M sold.

UBS Group first reported a position in RETA in Q2 2016 and held it in 28 quarters. The position peaked at $3.98M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

UBS Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
UBS Group sold 39,027 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $3.98M.
UBS Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 28 quarters.
UBS Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3.98M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.